Reported Saturday, Boston Scientific's HI-PEITHO Trial Shows EKOS Endovascular System Superior To Standard Of Care, Delivering 61% Reduction In Primary Endpoint Events In Acute Pulmonary Embolism

Boston Scientific Corporation +0.83%

Boston Scientific Corporation

BSX

61.79

+0.83%

Global randomized trial demonstrated statistically significant reduction in clinical event rates in patients with intermediate-risk PE when treated with the EKOS device plus anticoagulation vs. anticoagulation alone

Late breaking findings presented at ACC.26 and simultaneously published in The New England Journal of Medicine

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.